首页> 美国卫生研究院文献>Gut >Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.
【2h】

Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.

机译:自身免疫性肝炎和丙型肝炎病毒相关肝病中1型肝/肾微粒体抗体的异质性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Liver/kidney microsomal antibody type 1 (LKM-1), the serological marker of a subset of autoimmune hepatitis, is also present in a proportion of patients with hepatitis C virus (HCV) related chronic liver disease. To characterise further this autoreactivity and to evaluate whether an autoantibody giving an identical immunofluorescence staining, and detected in two different clinical conditions, involves the same antigenic target(s), sera from autoimmune and HCV infected patients were tested with native, recombinant, and synthetic antigens. Sixty five sera were selected on the basis of the typical immunofluorescence pattern: 50 patients had serological markers of HCV infection, the remaining 15 suffered from autoimmune hepatitis. The reactivity of each serum with rat and human microsomal fractions, full length human recombinant CYP2D6, and two synthetic peptides spanning the amino acid regions 257-269 and 373-398 of CYP2D6 was systematically investigated by immunoblotting. Fourteen (93%) sera from autoimmune hepatitis patients and 39 (78%) from HCV infected patients reacted with rat and/or human microsomal polypeptides of 39 kD, 50 kD, 58 kD, and 66 kD in different associations, the 50 kD band being the most frequently observed. Reactivity to CYP2D6 and its amino acid sequence 257-269 was significantly more common in autoimmune hepatitis than in HCV infected patients (p < 0.001 and p < 0.0003, respectively). LKM-1 reactivity is directed against heterogeneous and not entirely defined autoantigens. The main target in autoimmune sera is CYP2D6 and its 257-269 amino acid region, while sera from patients with HCV infection are more likely to recognise other microsomal targets, the molecular identity of which is currently unknown.
机译:一部分丙型肝炎病毒(HCV)相关的慢性肝病患者也存在肝/肾1型微粒体抗体(LKM-1),这是自身免疫性肝炎子集的血清学标志。为了进一步表征这种自身反应性并评估在两种不同临床条件下检测到的提供相同免疫荧光染色的自身抗体是否涉及相同的抗原靶标,对自身免疫和HCV感染患者的血清进行了天然,重组和合成测试抗原。根据典型的免疫荧光模式选择了65份血清:50例具有HCV感染血清学指标的患者,其余15例患有自身免疫性肝炎。通过免疫印迹系统地研究了每种血清与大鼠和人类微粒体级分,全长人类重组CYP2D6以及跨越CYP2D6氨基酸区域257-269和373-398的两个合成肽的反应性。来自自身免疫性肝炎患者的十四份(93%)血清和来自HCV感染患者的39份血清(39%(78%))与大鼠和/或39 kD,50 kD,58 kD和66 kD的微粒体多肽以不同的关联进行反应,50 kD谱带是最常观察到的。在自身免疫性肝炎中,对CYP2D6及其氨基酸序列257-269的反应比在HCV感染的患者中更为常见(分别为p <0.001和p <0.0003)。 LKM-1反应性针对异源且未完全定义的自身抗原。自身免疫血清的主要靶标是CYP2D6及其257-269个氨基酸区域,而HCV感染患者的血清更可能识别其他微粒体靶标,目前尚不清楚其分子身份。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号